原发纵隔大B细胞淋巴瘤60例临床病理特征及预后分析
回顾性分析60例原发纵隔大B细胞淋巴瘤(PMBL)的临床病理、免疫表型、免疫球蛋白基因重排及microRNA表达谱,发现其不同于弥漫大B细胞淋巴瘤;单因素分析显示LDH升高、IPI≥3、Ⅲ~Ⅳ期、未联合利妥昔单抗及MUM1阳性与预后差相关,多因素分析示联合利妥昔单抗是独立预后因素。
要点
- PMBL多见于年轻女性,中位年龄28岁,瘤细胞表达全B细胞抗原。
- 免疫组化CD30阳性77.4%、CD23阳性73.1%、MUM1阳性45.8%,Ki-67≥70%占90.6%。
- 联合利妥昔单抗治疗是影响生存的独立预后因素。
核心结论
- PMBL在临床病理特征、免疫表型及分子特征上不同于弥漫大B细胞淋巴瘤。
- 联合利妥昔单抗治疗是PMBL患者生存的独立预后因素。
研究设计与样本
- 回顾性纳入中日友好医院14例和北京协和医院46例,共60例PMBL,其中外检44例、会诊16例,时间2000年9月至2019年11月。
- 研究病理形态、免疫表型、免疫球蛋白基因重排及microRNA表达谱,并进行预后分析。
主要发现
- 60例中男性23例、女性37例,年龄15~64岁,中位年龄28岁。
- CD30阳性77.4%(24/31),CD23阳性73.1%(19/26),MUM1阳性45.8%(11/24),Ki-67指数≥70%占90.6%(29/32)。
- EBER检测21例中仅1例(4.8%)瘤细胞散在阳性;免疫球蛋白基因重排20例中7例阳性(35.0%)。
- 7例PMBL与9例弥漫大B细胞淋巴瘤microRNA表达谱比较,33个microRNA差异有统计学意义(P<0.05)。
- 单因素分析显示血清LDH升高、IPI评分≥3、临床分期Ⅲ~Ⅳ期、未联合利妥昔单抗化疗及MUM1阳性与生存率低、预后差相关(P<0.05)。
关键数值与推荐
- 多因素分析显示联合利妥昔单抗的治疗方案是影响患者生存时间的独立预后因素(P<0.05)。
临床怎么用
- 病理诊断PMBL需结合形态学、全B细胞抗原及CD30、CD23、MUM1等免疫表型。
- 预后评估可参考LDH、IPI评分、临床分期及MUM1状态,治疗应联合利妥昔单抗。
局限性
- 本研究为回顾性分析,部分检测项目病例数较少(如EBER 21例、基因重排20例、microRNA 7例对比9例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinicopathological features and prognostic factors of primary mediastinal large B-cell lymphoma (PMBL). Methods: The clinical data of 60 patients with PMBL including 44 biopsy cases and 16 consultation cases from September 2000 to November 2019 in the Department of Pathology, China-Japan Friendship Hospital (14 cases) and Peking Union Medical College Hospital (46 cases) were enrolled. Pathologic features, immunophenotype, immunoglobulin (Ig) gene rearrangement and microRNA expression profile were retrospectively studied. Results: Of the 60 patients, 23 were males and 37 were females, age ranged from 15 to 64 years (median 28 years). Immunohistochemical staining showed that the tumor cells were positive for pan-B cell antigens, CD30 (77.4%, 24/31), CD23 (73.1%, 19/26), MUM1 (45.8%, 11/24), Ki-67 index ≥70 % (90.6%, 29/32). EBER in situ hybridization was analyzed in 21 PMBL, only one case (4.8%) was positive. Ig gene rearrangement was performed in 20 cases, and seven were positive (35.0%). MicroRNA gene expression profiles were analyzed in seven cases of PMBL and nine cases of diffuse large B-cell lymphoma, and there were 33 microRNAs with significant difference (P<0.05). Univariate analysis indicated that the poor prognostic factors included serum lactate dehydrogenase (LDH) level,International Prognostic Index (IPI) score ≥3, stages Ⅲ-Ⅳ, chemotherapy not combined with rituximab and MUM1 positivity (P<0.05). Multivariate analysis showed that the treatment combined with rituximab was independently related to prognosis (P<0.05). Conclusions: PMBL is different from diffuse large B-cell lymphoma in clinicopathologic features, immunophenotypic presentation and molecular features. The prognostic factors, molecular genetics and immunological characteristics reveal that this study has enriched our understanding of the biology of PMBL, thus providing evidence and strategies for treatment. 目的: 探讨原发纵隔大B细胞淋巴瘤(PMBL)的临床病理特征及影响预后的相关因素。 方法: 回顾性分析中日友好医院(14例)和北京协和医院(46例)2000年9月至2019年11月外检(44例)及会诊(16例)共60例PMBL的临床资料、病理形态学特征、免疫表型、免疫球蛋白基因重排及microRNA表达谱。 结果: 60例患者中,男性23例,女性37例,年龄15~64岁(中位年龄28岁)。免疫组织化学染色表达全B细胞抗原,77.4%(24/31)的病例表达CD30,73.1%(19/26)表达CD23,45.8%(11/24)MUM1阳性,Ki-67阳性指数≥70%占90.6%(29/32);21例PMBL进行EB病毒编码的mRNA(EBER)检测,仅1例(4.8%)瘤细胞散在阳性;20例PMBL中的7例免疫球蛋白基因重排检测结果阳性(阳性率35.0%)。选取7例PMBL与9例弥漫大B细胞淋巴瘤作对照研究microRNA基因表达谱的差异,结果发现其表达差异有统计学意义的microRNA共计33个。单因素分析结果显示,血清乳酸脱氢酶(LDH)升高、临床分期Ⅲ~Ⅳ期、国际预后指数(IPI)评分≥3、未联合利妥昔单抗的化疗方案及免疫组织化学染色MUM1阳性的PMBL患者的生存率低,预后差(P<0.05);多因素分析结果显示其中联合利妥昔单抗的治疗方案是影响患者生存时间的独立预后因素(P<0.05)。 结论: PMBL从临床病理特征到免疫分子表型均不同于弥漫大B细胞淋巴瘤,本研究所揭示的预后因素、分子遗传学、免疫学特征丰富了对PMBL生物学的认识和理解,从而为治疗提供依据和策略。.
引用
- Liu HY, Zhong RQ, Zhang KP, et al. [Clinicopathological features and prognosis of primary mediastinal large B-cell lymphoma: a series of sixty cases]. Zhonghua Bing Li Xue Za Zhi. 2021. PMID: 34619867. doi:10.3760/cma.j.cn112151-20210115-00043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。